US · CHRS
Coherus Oncology, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Redwood City, CA 94065
- Website
- coherus.com
Price · as of 2024-12-31
$1.80
Market cap 201.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.40 | +1,533.33% |
| Intrinsic Value(DCF) | $0.42 | -76.67% |
| Graham-Dodd Method(GD) | $0.09 | -94.89% |
| Graham Formula(GF) | $2.93 | +62.67% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $28.96 | $456.75 | $30,652,727.23 | $0.00 | $0.00 |
| 2015 | $19.09 | $25.53 | $6.68 | $0.00 | $0.00 |
| 2016 | $23.45 | $63.10 | $271,620.66 | $0.00 | $0.00 |
| 2017 | $11.85 | $27.70 | $0.00 | $0.00 | $388.88 |
| 2018 | $14.01 | $25.33 | $0.00 | $0.00 | $0.00 |
| 2019 | $19.42 | $3,528.52 | $2,189.15 | $7.94 | $28,106.79 |
| 2020 | $16.25 | $85.78 | $2,157.81 | $13.18 | $74.57 |
| 2021 | $12.33 | $36.65 | $4.66 | $0.00 | $83.35 |
| 2022 | $6.07 | $18.59 | $0.00 | $0.00 | $96.70 |
| 2023 | $2.39 | $22.39 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.04 | $29.40 | $0.00 | $0.09 | $2.93 |
AI valuation
Our deep-learning model estimates Coherus Oncology, Inc.'s (CHRS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.40
- Current price
- $1.80
- AI upside
- +1,533.33%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.42
-76.67% upside
Graham-Dodd
$0.09
-94.89% upside
Graham Formula
$2.93
+62.67% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CHRS | Coherus Oncology, Inc. | $1.80 | 201.81M | +1,533% | -77% | -95% | +63% | 4.18 | -0.90 | 0.45 | 4.32 | — | -0.64 | 55.97% | -41.83% | 10.68% | -17.52% | -122.98% | 5.29% | -2.04 | -4.11 | 1.21 | 0.88 | 2.36 | -10988.00% | 378.00% | -8833.00% | -17.16% | -0.07 | -22.51% | 0.00% | 0.00% | 196.44% | -2.36 | -12.87 | 0.99 | -4.79 |
| AVTX | Avalo Therapeutics, Inc. | $17.50 | 197.65M | -16% | -59% | — | +1,518% | -1.80 | 0.47 | 143.03 | 1.04 | — | 0.51 | 182.99% | -15535.60% | -7965.76% | -50.06% | 26350.77% | -40.91% | 0.00 | — | 19.96 | 19.42 | 1.96 | -9713.00% | -7708.00% | 5908.00% | -77.77% | -7.05 | 18867.69% | 0.00% | 0.00% | 201.50% | 1.03 | 1.45 | -160.77 | -1.75 |
| CCCC | C4 Therapeutics, Inc. | $2.70 | 192.18M | +704% | -21% | — | — | -2.50 | 1.02 | 7.31 | -0.72 | — | 1.02 | 77.81% | -290.68% | -292.08% | -44.44% | -199.27% | -29.63% | 0.23 | — | 7.81 | 7.60 | 0.14 | -1645.00% | 102.00% | 5198.00% | -37.79% | -2.99 | -189.38% | 0.00% | 0.00% | 9.54% | -0.71 | -0.75 | 2.06 | -1.45 |
| CDXS | Codexis, Inc. | $1.01 | 91.23M | +2,411% | +12% | — | +481% | -3.17 | 3.09 | 3.49 | -3.31 | — | 3.21 | 72.55% | -98.61% | -109.99% | -85.03% | -128.77% | -45.72% | 0.89 | — | 4.18 | 3.90 | -0.69 | -2054.00% | -1539.00% | -586.00% | -25.95% | -2.09 | -118.20% | 0.00% | 0.00% | 0.00% | -3.31 | -3.60 | 3.26 | -4.07 |
| IMDX | Insight Molecular Diagnos… | $6.01 | 172.27M | +228% | -74% | — | — | -0.84 | -4.15 | 27.10 | -0.78 | -3.46 | -1.90 | 39.34% | -3245.14% | -3225.04% | -1480.67% | 3654.06% | -110.32% | -0.30 | -726.68 | 1.62 | 1.41 | 0.08 | 2430.00% | 2515.00% | -1007.00% | -41.64% | -2.85 | 1270.82% | 0.00% | 0.00% | 0.00% | -0.75 | -2.17 | 24.46 | -18.88 |
| IVVD | Invivyd, Inc. | $1.69 | 224.31M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| SGMO | Sangamo Therapeutics, Inc… | $0.43 | 160.68M | +6,900% | -3% | — | +6,207% | -2.14 | 9.21 | 3.63 | -2.23 | — | 9.21 | 100.00% | -179.88% | -169.45% | -185.39% | -403.81% | -73.38% | 1.34 | — | 1.13 | 1.02 | 0.13 | -6689.00% | -6720.00% | -7260.00% | -32.13% | -1.47 | -262.24% | 0.00% | 0.00% | 2.03% | -1.91 | -2.94 | 3.43 | -21.86 |
| SLS | SELLAS Life Sciences Grou… | $4.93 | 702.24M | — | — | — | — | -2.36 | 7.69 | — | 94.85 | — | 9.65 | 0.00% | — | — | -4147.88% | 484.07% | -240.78% | 0.11 | — | 1.72 | 1.46 | -20.39 | -6269.00% | — | -409.00% | -48.61% | -3.72 | 543.81% | 0.00% | 0.00% | 15.46% | -1.90 | -1.69 | — | -18.42 |
| TARA | Protara Therapeutics, Inc… | $6.36 | 245.43M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
- CEO
- Dennis Lanfear
- Employees
- 228
- Beta
- 1.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.42 ÷ $1.80) − 1 = -76.67% (DCF, example).